£1.4m · Other round · Healthtech · London, UK
London-based preventive healthcare platform Emerald has secured £1.4m in blended grant and venture funding. COVER reports that the package combines a £700k Innovate UK grant with £700k of venture investment. Existing investors, including Boost Capital Partners, participated alongside new backers Sequel and Highgoal Capital. The financing takes total funding to £2.9m and will support commercial expansion plus further product and clinical-service development.
Connecting tests to continuing clinical support
Emerald packages laboratory screening, wearable data and GP guidance into a preventive-care service. Its current product site offers annual or twice-yearly testing of up to 124 biomarkers, with results reviewed by clinicians and twelve months of access to the platform and medical team. Users can add earlier test results and data from more than 30 supported apps and devices to build a longitudinal health record rather than treating each screening as an isolated snapshot.
The commercial mechanism depends on closing the gap between measurement and action. A blood panel produces a momentary result; Emerald aims to turn that result into follow-up conversations, trend monitoring and practical changes that keep customers engaged after the appointment. That can create a longer relationship than a one-off test, but the value depends on whether the clinical layer changes behaviour and whether repeat testing shows useful progress, not simply on collecting more data.
Blended capital matches a regulated product roadmap
The split financing gives Emerald two different kinds of runway. Grant funding can support technology and clinical development that may need validation before it scales, while the venture portion can finance distribution and commercial execution. The company says it wants to reach one million members over the next three years, making acquisition efficiency and clinical capacity important constraints alongside software performance.
Emerald’s regulatory work raises that execution bar. The company says its app is a UKCA-marked Class I medical device, and co-founder Dr Dan McNally described the registration as an initial step toward higher-risk classifications as the platform’s capabilities expand. Moving from presenting health data toward more consequential AI-supported guidance would make clinical governance and regulatory scrutiny part of the product roadmap rather than a back-office concern.
